A Scotland Based Cost-Effectiveness Analysis Of Idelalisib (Zydelig®) In Combination With Rituximab For The Treatment Of Adults With Chronic Lymphocytic Leukaemia Cll)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1160
https://www.valueinhealthjournal.com/article/S1098-3015(15)03236-2/fulltext
Title :
A Scotland Based Cost-Effectiveness Analysis Of Idelalisib (Zydelig®) In Combination With Rituximab For The Treatment Of Adults With Chronic Lymphocytic Leukaemia Cll)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03236-2&doi=10.1016/j.jval.2015.09.1160
First page :
A455
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
659